Inhibrx Biosciences Inc (INBX) Stock Price, Quote & News

Company Profile

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lu...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 795 4220

Website: inhibrx.com

Address:

11025 North Torrey Pines Road, Suite 140, La Jolla, United States

Equibles Sep. 16 at 2:04 AM

$INBX Found it in the filings on Equibles. Inhibrx Biosciences, Inc. Chief Executive Officer Lappe Mark reported buying 9,681 INBX shares on September 8, 2026, worth about $1.09 million, in a non-derivative Form 4.

0 · Reply

Dmnaz Sep. 15 at 4:30 PM

$INBX what's your guys' take on this? I tend to be in the blockbuster camp. I think some read this and took some profits today. https://seekingalpha.com/article/4925607-inhibrx-biosciences-whole-story-rides-on-inbrxminus-106

2 · Reply

chefboobyflay Sep. 15 at 2:08 PM

$INBX Shorts just gonna take this for a ride back to $80 with no near term catalysts in sight.. I don’t see a takeout happening soon either. I’ll be buying but disappointed this hasn’t re-rated to the analyst price targets zone.

0 · Reply

BullStockpicks1 Sep. 14 at 4:38 PM

$INBX my updated post data analysis. Bottom line the future is really bright. https://x.com/bullstkpicks/status/2099472182451573157?s=46&t=cyjtCnUcMDe5-ZCjxf5y_w

1 · Reply

justiceforb_85 Sep. 14 at 2:47 AM

$INBX would love to see INBRX-106 get FDA BTD in metastatic HPV+ HNSCC.

1 · Reply

MBWallingford Sep. 12 at 2:26 PM

$INBX another flop read out. This one was worse at it really did not go up to the previous highs. Ok. They bought a tiny bit of shares? Small positive. Expanded scope -how will they pay? -dilution certainly coming. -delay monetization -no guarantee of accelerated approval -positive interim results. But they are not final. -pricing shows investors are not impressed. -very little volume. Why am I in this stock?

1 · Reply

TrendTrade8696 Sep. 12 at 1:11 PM

$INBX Short at $52.....

1 · Reply

TrendTrade8696 Sep. 12 at 1:07 PM

$INBX

0 · Reply

TrendTrade8696 Sep. 12 at 1:04 PM

$INBX

0 · Reply

CH_Expat Sep. 11 at 6:24 PM

$INBX Interesting. I am considering a position here and I always value your opinion. What makes you bearish?

0 · Reply

Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study

Sep 8, 2026, 8:00 AM EDT - 11 days ago

Inhibrx Biosciences Transcript: Study update

Sep 8, 2026, 8:00 AM EDT - 11 days ago

Inhibrx Biosciences Press release: Study update

Sep 8, 2026, 8:00 AM EDT - 11 days ago

Inhibrx Biosciences Slides: Study update

2026-09-08T11:40:40.000Z - 11 days ago

Inhibrx’s INBRX-106 achieves clinical benefit in Phase 2 HNSCC study

Sep 8, 2026, 7:30 AM EDT - 11 days ago

Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study

Sep 4, 2026, 4:00 PM EDT - 15 days ago

Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study

2026-08-24T10:10:50.000Z - 26 days ago

Inhibrx initiated with a Buy at H.C. Wainwright

Aug 13, 2026, 4:04 PM EDT - 5 weeks ago

Inhibrx Reports Second Quarter 2026 Financial Results

Aug 13, 2026, 7:00 AM EDT - 5 weeks ago

Inhibrx Biosciences Quarterly report: Q2 2026

Aug 13, 2026, 7:00 AM EDT - 5 weeks ago

Inhibrx Biosciences Earnings release: Q2 2026

Jul 16, 2026, 9:00 AM EDT - 2 months ago

Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million

2026-06-15T13:30:13.000Z - 3 months ago

Inhibrx announces FDA acceptance of BLA for ozekibart

Jun 15, 2026, 9:15 AM EDT - 3 months ago

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma

2026-05-15T13:15:11.000Z - 4 months ago

Inhibrx price target raised to $325 from $300 at Stifel

May 14, 2026, 4:02 PM EDT - 4 months ago

Inhibrx Reports First Quarter 2026 Financial Results

May 14, 2026, 7:00 AM EDT - 4 months ago

Inhibrx Biosciences Quarterly report: Q1 2026

2026-05-11T16:20:41.000Z - 4 months ago

Inhibrx’s INBRX-106 shows potential benefit in HNSCC

May 11, 2026, 8:30 AM EDT - 4 months ago

Inhibrx Biosciences Transcript: Study update

May 11, 2026, 8:30 AM EDT - 4 months ago

Inhibrx Biosciences Press release: Study update

May 11, 2026, 8:26 AM EDT - 4 months ago

This Surging Biotech Stock Shrugs Off Positive Cancer Trial Results and Slips. What to Know.

May 11, 2026, 8:00 AM EDT - 4 months ago

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy

May 8, 2026, 4:00 PM EDT - 4 months ago

Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC

2026-04-24T13:35:38.000Z - 4 months ago

Inhibrx initiated with an Outperform at LifeSci Capital

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Inhibrx Biosciences Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Inhibrx Biosciences Proxy statement: Proxy filing

2026-04-22T16:50:17.000Z - 5 months ago

Inhibrx price target raised to $300 from $150 at Stifel

2026-04-22T14:07:06.000Z - 5 months ago

Inhibrx trading halted, volatility trading pause

2026-04-22T14:01:35.000Z - 5 months ago

Inhibrx trading resumes

2026-04-22T12:50:13.000Z - 5 months ago

Inhibrx’s cancer drug drawing interest from Merck, Ono, Reuters says

MRK

2026-04-22T12:49:00.000Z - 5 months ago

Inhibrx up 39% at $117 after report of interest from Merck in cancer assets

Apr 22, 2026, 7:02 AM EDT - 5 months ago

Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say

MRK

Apr 21, 2026, 4:30 PM EDT - 5 months ago

Inhibrx Biosciences Transcript: Study update

Apr 21, 2026, 4:30 PM EDT - 5 months ago

Inhibrx Biosciences Press release: Study update

2026-04-21T20:24:03.000Z - 5 months ago

Inhibrx reports interim data from its Phase 1/2 study evaluating ozekibart

Apr 21, 2026, 4:05 PM EDT - 5 months ago

Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

Apr 21, 2026, 7:00 AM EDT - 5 months ago

Inhibrx Biosciences Slides: Investor presentation

Apr 20, 2026, 5:03 PM EDT - 5 months ago

Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

2026-04-07T20:17:46.000Z - 5 months ago

Inhibrx initiated with a Buy at Stifel

Mar 19, 2026, 6:00 PM EDT - 6 months ago

Inhibrx Biosciences Earnings release: Q4 2025

Mar 19, 2026, 6:00 PM EDT - 6 months ago

Inhibrx Biosciences Annual report: Q4 2025

2026-03-19T20:10:58.000Z - 6 months ago

Inhibrx reports Q4 EPS ($2.11) vs. ($3.09) last year

Mar 19, 2026, 4:00 PM EDT - 6 months ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Mar 12, 2026, 7:00 AM EDT - 6 months ago

Inhibrx Biosciences Slides: Investor presentation

Mar 2, 2026, 4:00 PM EST - 6 months ago

Inhibrx Announces Participation in Upcoming Scientific Conference

Jan 22, 2026, 10:26 AM EST - 8 months ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE KOD LITE

2025-12-16T22:10:33.000Z - 9 months ago

Inhibrx provides update on INBRX-106 Phase 2/3 clinical trial

Dec 16, 2025, 5:00 PM EST - 9 months ago

Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

Nov 14, 2025, 6:00 AM EST - 10 months ago

Inhibrx Reports Third Quarter 2025 Financial Results

Nov 13, 2025, 6:00 PM EST - 10 months ago

Inhibrx Biosciences Quarterly report: Q3 2025

Nov 13, 2025, 6:00 PM EST - 10 months ago

Inhibrx Biosciences Earnings release: Q3 2025

Nov 4, 2025, 4:01 PM EST - 10 months ago

Inhibrx Announces Participation in Upcoming Scientific Conferences

Oct 23, 2025, 6:39 PM EDT - 11 months ago

Inhibrx shares surge after bone cancer drug slows disease progression in trial

Oct 23, 2025, 4:30 PM EDT - 11 months ago

Inhibrx Biosciences Transcript: Study Result

Oct 23, 2025, 4:30 PM EDT - 11 months ago

Inhibrx Biosciences Press release: Study Result

Oct 23, 2025, 4:05 PM EDT - 11 months ago

Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

Oct 22, 2025, 4:01 PM EDT - 11 months ago

Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

Aug 13, 2025, 4:05 PM EDT - 1 year ago

Inhibrx Reports Second Quarter 2025 Financial Results

Aug 12, 2025, 6:00 PM EDT - 1 year ago

Inhibrx Biosciences Quarterly report: Q2 2025

Aug 12, 2025, 6:00 PM EDT - 1 year ago

Inhibrx Biosciences Earnings release: Q2 2025

May 14, 2025, 4:05 PM EDT - 1 year ago

Inhibrx Reports First Quarter 2025 Financial Results

May 14, 2025, 8:00 AM EDT - 1 year ago

Inhibrx Biosciences Quarterly report: Q1 2025

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Inhibrx Biosciences Proxy statement: Proxy filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Inhibrx Biosciences Proxy statement: Proxy filing

Apr 1, 2025, 4:05 PM EDT - 1 year ago

Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

Mar 17, 2025, 4:05 PM EDT - 1 year ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Mar 16, 2025, 7:00 PM EDT - 1 year ago

Inhibrx Biosciences Earnings release: Q4 2024

Mar 16, 2025, 7:00 PM EDT - 1 year ago

Inhibrx Biosciences Annual report: Q4 2024

Jan 21, 2025, 5:01 PM EST - 1 year ago

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer

Jan 13, 2025, 4:15 PM EST - 1 year ago

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance

Nov 14, 2024, 4:24 PM EST - 1 year ago

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results

Nov 14, 2024, 7:00 AM EST - 1 year ago

Inhibrx Biosciences Quarterly report: Q3 2024

Nov 4, 2024, 4:00 PM EST - 1 year ago

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation

Aug 13, 2024, 6:54 PM EDT - 2 years ago

Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Aug 13, 2024, 8:00 AM EDT - 2 years ago

Inhibrx Biosciences Quarterly report: Q2 2024

Jun 11, 2024, 8:00 AM EDT - 2 years ago

Inhibrx Biosciences Registration statement: Registration filing

May 24, 2024, 4:00 PM EDT - 2 years ago

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

May 21, 2024, 8:00 AM EDT - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

May 17, 2024, 8:00 AM EDT - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

May 10, 2024, 6:36 PM EDT - 2 years ago

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off

May 9, 2024, 3:36 PM EDT - 2 years ago

INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX

SNY

May 8, 2024, 4:37 PM EDT - 2 years ago

Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Feb 29, 2024, 7:00 AM EST - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Feb 28, 2024, 9:15 AM EST - 2 years ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Feb 28, 2024, 7:00 AM EST - 2 years ago

Inhibrx Biosciences Annual report: Q4 2023

Feb 6, 2024, 7:00 AM EST - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Jan 23, 2024, 11:45 AM EST - 2 years ago

Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline

SNY

Jan 23, 2024, 7:00 AM EST - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Jan 23, 2024, 7:00 AM EST - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Jan 23, 2024, 5:39 AM EST - 2 years ago

Sanofi to Buy Rare-Disease Assets From Inhibrx

SNY

Jan 23, 2024, 1:32 AM EST - 2 years ago

France's Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 bln

SNY

Jan 23, 2024, 1:30 AM EST - 2 years ago

Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline

SNY

Jan 23, 2024, 1:00 AM EST - 2 years ago

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

SNY

Nov 9, 2023, 4:00 PM EST - 2 years ago

Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Nov 2, 2023, 9:15 AM EDT - 2 years ago

Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

Sep 19, 2023, 4:00 PM EDT - 3 years ago

Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada

Sep 1, 2023, 4:26 PM EDT - 3 years ago

Andreas Halvorsen's Firm Ups Inhibrx Stake

Aug 29, 2023, 9:00 AM EDT - 3 years ago

Inhibrx Announces $200 Million Private Placement Financing

Aug 7, 2023, 4:00 PM EDT - 3 years ago

Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

May 30, 2023, 9:00 AM EDT - 3 years ago

Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

Equibles Sep. 16 at 2:04 AM

0 · Reply

Dmnaz Sep. 15 at 4:30 PM

2 · Reply

chefboobyflay Sep. 15 at 2:08 PM

0 · Reply

BullStockpicks1 Sep. 14 at 4:38 PM

$INBX my updated post data analysis. Bottom line the future is really bright. https://x.com/bullstkpicks/status/2099472182451573157?s=46&t=cyjtCnUcMDe5-ZCjxf5y_w

1 · Reply

justiceforb_85 Sep. 14 at 2:47 AM

$INBX would love to see INBRX-106 get FDA BTD in metastatic HPV+ HNSCC.

1 · Reply

MBWallingford Sep. 12 at 2:26 PM

1 · Reply

TrendTrade8696 Sep. 12 at 1:11 PM

$INBX Short at $52.....

1 · Reply

TrendTrade8696 Sep. 12 at 1:07 PM

$INBX

0 · Reply

TrendTrade8696 Sep. 12 at 1:04 PM

$INBX

0 · Reply

CH_Expat Sep. 11 at 6:24 PM

$INBX Interesting. I am considering a position here and I always value your opinion. What makes you bearish?

0 · Reply

Terzman Sep. 11 at 12:12 PM

$INBX lets repeat an obvious … no raise on landscape… loan facility in hand .. insiders bought here in size.. = message to shorts = gfys

0 · Reply

Mike22332233 Sep. 10 at 2:28 PM

$SLS 👉 8 BUY OUTs in 8 Months ... I Will Almost Guarantee It !!!! EIGHT, or more, of the following of my Special Situation Stocks will be Bought Out: 1) SLS 2) $INBX 3) $PRTH 4) $DDI 5) $MNRO 6) RYAM 7) CRTO 8) GFL 9) IMXI 10) QGEN 11) PBI 12) BVS 13) ASH 14) CCC LIKE & FOLLOW Me 👉@Mike22332233 for the latest updates on each !!!

3 · Reply

MBWallingford Sep. 9 at 10:46 PM

$INBX the readout was a hype event that was not positive. The fact is the final report is now delayed. I think the investors do not look at it as positive. Approval for the medication is now delayed. Maybe it is offset by accelerated approval. Horrible communication by the CEO and company. Positive that the CEO bought shares but he already had a ton of shares. Yes positive interim data but investor don’t seem to care. They must be waiting for final results. The we have phase 3 testing. They don’t have the cash to make it to approval. They will need to dilute. No meaningful change after readout and stock ran up due to hopium. I think we could drift back to $80 again. Yeah the cheerleaders will bash this post but I think this the right to look at the stock.

2 · Reply

CH_Expat Sep. 9 at 2:44 PM

$INBX Nice fake shakeout yesterday. Wanted to make you think data was bad.

1 · Reply

CEOBuysDisclosures Sep. 8 at 10:10 PM

$INBX CEO purchased 25,000 shares at $105.82 for a total of $2,645,399. Lappe Mark now owns 950,413 shares. https://ceo-buys.com

0 · Reply

Terzman Sep. 8 at 9:50 PM

$INBX kudos to ceo great add _ in a tape that was clearly dominated by short effort .. this will indeed show today was oppty for buyers

0 · Reply

stny Sep. 8 at 8:39 PM

$INBX CEO sounded confident/bullish on the call. Great to see him put his money where his mouth is!

0 · Reply

FilingTracker Sep. 8 at 8:05 PM

$INBX CEO purchase: https://filingtracker.ai/filing/1366074/0001366074-26-000002?doc=wk-form4_1788897881.xml

0 · Reply

Barrington787 Sep. 8 at 6:49 PM

$INBX I think because of expanded scope final results will be delayed.

0 · Reply

CH_Expat Sep. 8 at 6:46 PM

$KARD $GLUE $INBX are candidates for new positions. I will wait for lower though. Re-Entering $VERA under 30 without hesitating.

0 · Reply

Barrington787 Sep. 8 at 6:06 PM

$INBX well this is certainly disappointing. Horrible communication. Somebody should get fired over this.

1 · Reply

justiceforb_85 Sep. 8 at 5:57 PM

$INBX data looks pretty good. IMO this is undervalued given the validation we're seeing with 106 with OX40 agonism which has failed repeatedly by many other companies.

0 · Reply

Market Cap	1.61B
Revenue (ttm)	1.30M
Net Income (ttm)	-140.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-10,773.85%
Debt to Equity Ratio	-3.33

Volume	483,300
Avg Vol	296,260
Day's Range	N/A - N/A
Shares Out	14.72M
Stochastic %K	44%
Beta	3.66
Analysts	Strong Sell
Price Target	$266.67